Secukinumab is a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing
Cat.No
A019
Name
Secukinumab
Chemical Properties
CAS
1229022-83-6
Synonyms
Immunoglobulin G1, anti-(human interleukin-17A), human monoclonal AIN457 γ1 heavy chain (230-215')-disulfide with human monoclonal AIN457 κ light chain dimer (236-236'':239-239'')-bisdisulfide;Secukinumab;Research Grade Secukinumab(DHH28802);Research Grade Secukinumab(DHH28802);AIN 457;AIN 457;AIN457;AIN457;AIN-457;AIN-457;Secukinumab (anti-IL-17A);Secukinumab (anti-IL-17A)
pH value
Corresponds to reference standard： PASS
Non-reduced CE-SDS
98.8%
SEC-HPLC
99.1%
Isoelectric Point
Corresponds to reference standard:PASS
Bacterial Endotoxins Test
＜1 EU/ml
Residual Proteins of Host Cell
Exogenous Residual DNA
＜1 pg/mg
Residual protein A
＜1 ng/mg
Biological Activity
Compared with standard, the range of biological activity is 112%
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard:PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
